Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBCBS Tennessee Keytruda Qlex Coverage | OpenPayer
    Ask Trek AI about this page
    DraftBlue Cross Blue Shield - TennesseePolicy ID_CHS_71972026b_1126

    Pembrolizumab and Berahyaluronidase alfa-pmph (Keytruda Qlex)

    Customize your policy alerts

    Sign up for blue cross blue shield - tennessee Policy ID_CHS_71972026b_1126 alerts

    Get alerted when Policy ID_CHS_71972026b_1126 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage of Keytruda Qlex for listed FDA-approved oncology indications when approval criteria are met and the member has no exclusions. Benefit-plan terms and applicable government programs control when they conflict with the policy.

    Policy Summary
    PayerBlue Cross Blue Shield - Tennessee
    PolicyPembrolizumab and Berahyaluronidase alfa-pmph (Keytruda Qlex)
    Policy CodePolicy ID_CHS_71972026b_1126
    Change TypeNo material change
    Effective DateJan 30, 2027
    Next Review DateN/A
    Key ActionSubmit applicable tumor biomarker, molecular, receptor, and laboratory documentation with the prior authorization request.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    FDA-approved indicationsCoverage basis
    6 monthsStandard authorization
    Biomarker testingDocumentation required
    2Explicit exclusions

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Subcutaneous
    Administration

    Covered Indications and Eligibility

    Covered FDA-Approved Indications and Compendial Uses

    Covered when the requested therapy is an FDA-approved indication or covered compendial use, all applicable approval criteria are met, and the member has no exclusion to the prescribed therapy.

    ALL of the following

    • The requested medication is used for an indication listed in the coverage criteria.
    • All disease, biomarker, treatment-setting, and regimen requirements for the applicable indication are met.
    • The member has no applicable exclusion.

    Cutaneous Melanoma

    Authorization of 6 months may be granted when ALL applicable criteria are met.

    ANY of the following settings

    • Unresectable or metastatic melanoma treated as a single agent.
    • Subsequent therapy for metastatic or unresectable disease in combination with lenvatinib.
    • Neoadjuvant treatment as a single agent.
    • Adjuvant treatment following complete lymph node resection or complete resection of stage IIB, IIC, or III disease as a single agent in a member age 12 years or older.
    • Subsequent or re-induction therapy in combination with trametinib and dabrafenib for metastatic or unresectable disease with a BRAF V600 activating mutation.

    Non-Small Cell Lung Cancer

    Authorization of 6 months may be granted for recurrent, advanced, or metastatic NSCLC when applicable molecular testing requirements and one covered treatment pathway are met.

    ALL of the following

    • There are no EGFR exon 19 deletions or exon 21 L858R mutations, or ALK, RET, or ROS1 gene fusions, unless testing is not feasible because of insufficient tissue.
    • ANY of the following

      • Single-agent treatment for PD-L1-positive disease.
      • Single-agent treatment or treatment in combination with pemetrexed for maintenance therapy.
      • Combination with pemetrexed and carboplatin or cisplatin for nonsquamous histology.

    Head and Neck Cancer

    Authorization of 6 months may be granted when the disease setting, biomarker, and treatment requirements are met.

    ANY of the following

    • Resectable stage III-IVa non-nasopharyngeal HNSCC with PD-L1 ≥1, treated as a single agent neoadjuvantly, then with radiotherapy with or without cisplatin as adjuvant therapy, followed by single-agent therapy.
    • Very advanced HNSCC, mixed-subtype HNSCC, or nasopharyngeal cancer treated as a single agent first line for PD-L1 CPS ≥1, MSI-H, dMMR, or TMB-H ≥10 mut/Mb disease.
    • Very advanced HNSCC, mixed-subtype HNSCC, or nasopharyngeal cancer treated as single-agent subsequent therapy.
    • Very advanced HNSCC, mixed-subtype HNSCC, or nasopharyngeal cancer treated in combination with cetuximab or chemotherapy.
    • Recurrent salivary gland tumors that are MSI-H, dMMR, TMB-H ≥10 mut/Mb, or PD-L1 positive, treated as a single agent.

    Non-Small Cell Lung Cancer — Neoadjuvant or Adjuvant Use

    Authorization of 6 months may be granted for qualifying resectable NSCLC.

    ALL of the following

    • The disease is resectable, with tumors ≥4 cm or node-positive disease.
    • The requested medication is used neoadjuvantly with platinum-containing chemotherapy or as adjuvant single-agent therapy after adjuvant chemotherapy or qualifying neoadjuvant therapy.
    • There are no EGFR exon 19 deletions or exon 21 L858R mutations, or ALK, RET, or ROS1 gene fusions, unless testing is not feasible because of insufficient tissue.

    Head and Neck Cancer — Covered Disease Settings

    Authorization of 6 months may be granted for covered HNSCC disease settings.

    ANY of the following

    • Resectable stage III-IVa non-nasopharyngeal HNSCC with PD-L1 ≥1, using neoadjuvant single-agent therapy, adjuvant radiotherapy with or without cisplatin, and subsequent single-agent therapy.
    • Very advanced HNSCC or mixed-subtype HNSCC treated as first-line single-agent therapy for PD-L1 CPS ≥1, MSI-H, dMMR, or TMB-H ≥10 mut/Mb disease.
    • Very advanced HNSCC or mixed-subtype HNSCC treated as subsequent single-agent therapy or in combination with cetuximab or chemotherapy.
    • Nasopharyngeal cancer treated under one of the preceding covered pathways.
    • Recurrent salivary gland tumor that is MSI-H, dMMR, TMB-H ≥10 mut/Mb, or PD-L1 positive, treated as a single agent.

    Urothelial Carcinoma

    Authorization of 6 months may be granted for urothelial carcinoma in any qualifying disease location and treatment setting.

    ANY of the following

    • Bladder urothelial carcinoma: stage II, recurrent, locally advanced, or metastatic disease treated first line, subsequently, or adjuvantly; or high-risk BCG-unresponsive NMIBC with CIS when the member will not undergo cystectomy.
    • Primary urethral carcinoma: locally advanced, recurrent, or metastatic disease when not eligible for platinum chemotherapy; recurrent or metastatic disease after platinum or other chemotherapy; or adjuvant therapy.
    • Upper genitourinary tract urothelial carcinoma: metastatic disease when not eligible for platinum chemotherapy; metastatic disease after platinum or other chemotherapy; or adjuvant therapy after platinum-based neoadjuvant chemotherapy.
    • Urothelial carcinoma of the prostate: metastatic disease when not eligible for platinum chemotherapy; metastatic disease after platinum or other chemotherapy; or adjuvant therapy when platinum-based neoadjuvant chemotherapy was not given.

    Biomarker-Positive Solid Tumors

    Authorization of 6 months may be granted as a single agent when ALL criteria are met.

    ALL of the following

    • The tumor is an unresectable or metastatic solid tumor that has progressed following prior treatment.
    • There is no satisfactory alternative treatment option.
    • The tumor meets ONE of these biomarker criteria

      • Microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR).
      • Tumor mutational burden-high (TMB-H), ≥10 mutations/megabase.

    Anaplastic Thyroid Carcinoma

    Authorization of 6 months may be granted as a single agent or in combination with lenvatinib.

    ALL of the following

    • The diagnosis is stage IVC anaplastic thyroid carcinoma.
    • The requested medication is used as a single agent or with lenvatinib.

    Follicular, Oncocytic, or Papillary Thyroid Carcinoma

    Authorization of 6 months may be granted when ALL criteria are met.

    ALL of the following

    • The disease is follicular, oncocytic (Hürthle cell), or papillary thyroid carcinoma and is locoregional, unresectable, progressive and/or symptomatic, or metastatic.
    • Radioactive iodine therapy is not indicated, contraindicated, or has been unsuccessful.
    • ONE of the following

      • The disease is MSI-H, dMMR, or TMB-H ≥10 mut/Mb.
      • The disease progressed on single-agent lenvatinib and the requested medication will be combined with lenvatinib.

    Colorectal Cancer

    Authorization of 6 months may be granted as a single agent.

    ALL of the following

    • The diagnosis is colorectal cancer, including appendiceal neoplasm or carcinoma.
    • The tumor has ONE of the following biomarker profiles

      • MSI-H.
      • dMMR.
      • POLE/POLD1 mutation with an ultra-hypermutated phenotype, TMB >50 mut/Mb.

    Small Bowel Adenocarcinoma

    Authorization of 6 months may be granted as a single agent in any qualifying small bowel adenocarcinoma setting.

    ANY of the following

    • Neoadjuvant therapy for MSI-H, dMMR, or POLE/POLD1 ultra-hypermutated tumors with TMB >50 mut/Mb.
    • Unresectable or medically inoperable disease with MSI-H, dMMR, or POLE/POLD1 ultra-hypermutated tumors with TMB >50 mut/Mb.
    • Advanced or metastatic disease with TMB-H ≥10 mut/Mb, MSI-H, dMMR, or POLE/POLD1 ultra-hypermutated tumors with TMB >50 mut/Mb.

    Merkel Cell Carcinoma

    Authorization of 6 months may be granted as a single agent.

    ALL of the following

    • The member is age 12 years or older.
    • The disease is locally advanced, regional, recurrent, or metastatic Merkel cell carcinoma.

    Cervical Cancer

    Authorization of 6 months may be granted in any qualifying setting.

    ANY of the following

    • Persistent, recurrent, or metastatic disease treated with chemotherapy with or without bevacizumab for PD-L1 CPS ≥1 disease.
    • Recurrent or metastatic disease treated as a single agent or with tisotumab vedotin-tftv as subsequent therapy for PD-L1 CPS ≥1 or MSI-H/dMMR disease.
    • FIGO stage III-IVA disease treated with chemoradiation.

    Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

    Authorization of 6 months may be granted for the following ovarian, fallopian tube, primary peritoneal, and related histologies.

    ANY of the following

    • Single-agent treatment for recurrent or persistent MSI-H, dMMR, or TMB-H ≥10 mut/Mb epithelial ovarian, fallopian tube, primary peritoneal, carcinosarcoma, clear cell, mucinous, grade 1 endometrioid, low-grade serous, or malignant germ cell tumors.
    • Combination with oral cyclophosphamide and bevacizumab for recurrent or persistent epithelial ovarian, fallopian tube, primary peritoneal, carcinosarcoma, clear cell, mucinous, grade 1 endometrioid, or low-grade serous carcinoma.
    • Subsequent treatment of platinum-resistant or recurrent disease in combination with paclitaxel, with or without bevacizumab, when PD-L1 CPS ≥1.
    • Single-agent treatment for progressive or recurrent small cell carcinoma of the ovary, hypercalcemic type.

    Uveal Melanoma

    Authorization of 6 months may be granted as a single agent.

    ALL of the following

    • The disease is unresectable or metastatic uveal melanoma.

    Endometrial Carcinoma

    Authorization of 6 months may be granted in any qualifying endometrial carcinoma pathway.

    ANY of the following

    • Combination with lenvatinib for advanced, metastatic, or recurrent pMMR endometrial carcinoma.
    • Combination with lenvatinib for dMMR endometrial carcinoma that progressed after platinum-based chemotherapy.
    • Single-agent treatment for recurrent unresectable or metastatic MSI-H, dMMR, or TMB-H ≥10 mut/Mb disease.
    • Combination with carboplatin and paclitaxel followed by single-agent maintenance therapy for stage III-IV or recurrent disease, for up to 20 cycles total.

    Anal Carcinoma

    Authorization of 6 months may be granted in either covered setting.

    ANY of the following

    • Combination with paclitaxel and carboplatin for recurrent or metastatic anal carcinoma.
    • Single-agent subsequent therapy for metastatic anal carcinoma.

    Anal Carcinoma, CNS Metastases, and Pancreatic Adenocarcinoma

    Authorization of 6 months may be granted for any applicable disease and treatment setting.

    ANY of the following

    • Recurrent or metastatic anal carcinoma treated with paclitaxel and carboplatin or single-agent subsequent therapy.
    • CNS brain metastases treated as a single agent in BRAF-nonspecific melanoma or PD-L1-positive NSCLC.
    • Recurrent, locally advanced, or metastatic pancreatic adenocarcinoma with MSI-H, dMMR, or TMB-H ≥10 mut/Mb disease, treated as a single agent.

    Biliary Tract Cancers

    Authorization of 6 months may be granted in any qualifying biliary tract cancer pathway.

    ANY of the following

    • Locally advanced unresectable, gross residual (R2), or metastatic disease treated with gemcitabine and cisplatin or carboplatin.
    • Unresectable, gross residual (R2), or metastatic intrahepatic or extrahepatic cholangiocarcinoma or gallbladder cancer that is MSI-H, dMMR, or TMB-H ≥10 mut/Mb, treated as a single agent.
    • Neoadjuvant treatment of resectable locoregionally advanced gallbladder cancer with cisplatin or carboplatin plus gemcitabine.
    • Neoadjuvant single-agent treatment of resectable locoregionally advanced gallbladder cancer with MSI-H and/or dMMR disease.

    Hepatocellular Carcinoma

    Authorization of 6 months may be granted for hepatocellular carcinoma when ANY criterion is met.

    ANY of the following

    • HCC secondary to hepatitis B, after prior systemic therapy other than a PD-1/PD-L1-containing regimen, treated as a single agent.
    • Single-agent subsequent therapy for HCC.

    Additional Solid Tumor Indications

    Authorization of 6 months may be granted for the following additional solid tumor indications.

    ANY of the following

    • Advanced, recurrent, or metastatic vulvar cancer treated as subsequent single-agent therapy or with chemotherapy with or without bevacizumab.
    • Advanced, relapsed, or stage IV renal cell carcinoma treated first line as a single agent or with axitinib; subsequent therapy with axitinib for clear-cell disease; with lenvatinib; as a single agent for non-clear-cell disease; or adjuvantly after nephrectomy with intermediate-high or high recurrence risk or after nephrectomy and metastatic-lesion resection.
    • Recurrent, unresectable, advanced, or metastatic thymic carcinoma treated as a single agent, or postoperative therapy when first-line combination regimens cannot be tolerated.
    • Multi-agent chemotherapy-resistant gestational trophoblastic neoplasia treated as a single agent for recurrent/progressive intermediate trophoblastic tumor or high-risk disease.

    Cutaneous Squamous Cell Carcinoma, Soft Tissue Sarcoma, and Occult Primary Cancer

    Authorization of 6 months may be granted when the applicable disease-specific criteria are met.

    ANY of the following

    • Locally advanced, recurrent, metastatic, or satellitosis/in-transit cutaneous squamous cell carcinoma when curative radiation or surgery is not feasible, treated as a single agent.
    • Soft tissue sarcoma meeting a covered subtype and regimen pathway.
    • Occult primary cancer with MSI-H, dMMR, or TMB-H ≥10 mut/Mb tumors, treated as a single agent.

    Breast Cancer

    Authorization of 6 months may be granted when all applicable biomarker and regimen criteria are met.

    ANY of the following

    • ALL of the following

      • Locally recurrent unresectable or metastatic triple-negative breast cancer with HER2, estrogen, and progesterone receptor-negative testing, PD-L1 CPS ≥10, and treatment in combination with sacituzumab govitecan-hziy or chemotherapy.
    • ALL of the following

      • High-risk early-stage triple-negative breast cancer with HER2, estrogen, and progesterone receptor-negative testing.
      • Neoadjuvant combination with chemotherapy or continued single-agent adjuvant treatment after surgery.
    • ALL of the following

    Prostate Cancer and Pediatric Diffuse High-Grade Gliomas

    Authorization of 6 months may be granted for the following indications.

    ANY of the following

    • Castration-resistant distant metastatic prostate cancer with TMB ≥10 mutations/megabase, treated as a single agent.
    • Pediatric diffuse high-grade glioma with a hypermutant tumor treated adjuvantly, or recurrent or progressive disease treated under the covered pathway.

    Prostate Cancer

    Authorization of 6 months may be granted as a single agent.

    ALL of the following

    • The member has castration-resistant distant metastatic prostate cancer.
    • The tumor has TMB ≥10 mutations/megabase.

    Pediatric Diffuse High-Grade Gliomas

    Authorization of 6 months may be granted for either qualifying condition.

    ANY of the following

    • Adjuvant treatment of a hypermutant pediatric diffuse high-grade glioma.
    • Treatment of recurrent or progressive pediatric diffuse high-grade glioma.

    Ampullary Adenocarcinoma

    Authorization of 6 months may be granted as a single agent.

    ALL of the following

    • The diagnosis is ampullary adenocarcinoma.
    • ANY of the following

      • MSI-H disease.
      • dMMR disease.
      • TMB-H ≥10 mut/Mb disease.

    Vaginal Cancer

    Authorization of 6 months may be granted in either covered vaginal cancer pathway.

    ANY of the following

    • Combination with cisplatin or carboplatin and paclitaxel, with or without bevacizumab, for recurrent or metastatic PD-L1-positive disease with CPS ≥1.
    • Single-agent subsequent treatment for recurrent or metastatic PD-L1-positive disease or MSI-H, dMMR, or TMB-H ≥10 mut/Mb disease.

    Pleural or Peritoneal Mesothelioma

    Authorization of 6 months may be granted for first-line treatment.

    ALL of the following

    • The diagnosis is pleural or peritoneal mesothelioma, including pericardial mesothelioma or tunica vaginalis testis mesothelioma.
    • The requested medication is used in combination with pemetrexed and platinum chemotherapy.

    Penile Cancer

    Authorization of 6 months may be granted when either treatment pathway is met.

    ANY of the following

    • First-line combination with fluorouracil and cisplatin or carboplatin, followed by single-agent maintenance therapy, for recurrent or metastatic penile cancer.
    • Single-agent subsequent therapy for unresectable or metastatic MSI-H, dMMR, or TMB-H ≥10 mut/Mb penile cancer.

    Continuation of Therapy for Listed Cancers

    Authorization of 6 months may be granted for continued treatment when the member has not experienced disease progression or unacceptable toxicity.

    Applicable continuation pathway

    • Continued treatment for NSCLC, HNSCC, MSI-H/dMMR cancers, gastric cancer, esophageal or EGJ cancer, cervical cancer, HCC, MCC, RCC, endometrial carcinoma, cSCC, TNBC, TMB-H cancer, biliary tract cancer, pleural or peritoneal mesothelioma, penile cancer, chordoma, thyroid carcinoma, neuroendocrine or adrenal tumors, uveal melanoma, vaginal cancer, CNS brain metastases, vulvar cancer, thymic carcinoma, gestational trophoblastic neoplasia, or anal carcinoma, for up to 24 months of continuous use.
    • Continued treatment for a listed indication when disease has not progressed and toxicity remains acceptable.

    Adjuvant Melanoma, HNSCC, TNBC, RCC, or NSCLC

    Authorization of 6 months may be granted, up to 12 months total, when there has been no recurrence or unacceptable toxicity.

    ANY of the following adjuvant indications

    • Adjuvant cutaneous melanoma.
    • Adjuvant HNSCC.
    • Adjuvant triple-negative breast cancer.
    • Adjuvant RCC.
    • Adjuvant NSCLC.

    Soft Tissue Sarcoma

    Authorization of 6 months may be granted for continued treatment without disease progression or unacceptable toxicity.

    ANY of the following

    • Continued treatment of alveolar soft part sarcoma in combination with axitinib, for up to 26 months total.
    • Continued single-agent treatment of soft tissue sarcoma, for up to 24 months total.

    Cutaneous Melanoma

    Authorization of 6 months may be granted for continued cutaneous melanoma treatment when the applicable duration and disease-control requirements are met.

    ANY of the following

    • Continued adjuvant treatment after melanoma resection, up to 12 months total, without recurrence or unacceptable toxicity.
    • Continued treatment of metastatic or unresectable melanoma in combination with lenvatinib without progression or unacceptable toxicity.
    • Continued treatment of cutaneous melanoma for up to 24 months of continuous use without progression or unacceptable toxicity.

    Urothelial Carcinoma

    Authorization of 6 months may be granted for continued urothelial carcinoma treatment when disease control and duration requirements are met.

    ANY of the following

    • Continued adjuvant treatment, up to 12 months total, without recurrence or unacceptable toxicity.
    • Continued combination treatment with enfortumab vedotin-ejfv without progression or unacceptable toxicity.
    • Continued urothelial carcinoma treatment for up to 24 months of continuous use without progression or unacceptable toxicity.

    All Other Indications

    Authorization of 6 months may be granted for continued treatment of an indication listed in the coverage criteria section when the member has not experienced disease progression or unacceptable toxicity.

    ALL of the following

    • The indication is listed in the coverage criteria section.
    • The member has not experienced disease progression.
    • The member has not experienced unacceptable toxicity.

    Initial Authorization Pathways

    Disease-specific initial authorization — 6-month authorization when criteria are met

    Initial or requested therapy may qualify for 6-month authorization when the applicable disease-specific criteria are met.

    Disease-specific initial authorization: The requested regimen meets one of the covered cutaneous melanoma, NSCLC, or head and neck cancer criteria.6-month authorization

    Initial oncology authorization — disease-specific indications and regimens

    Initial authorization is available for the disease-specific indications and regimens described in the policy.

    Disease-specific indication: The requested medication meets the applicable clinical, biomarker, treatment-line, prior-therapy, surgical-candidacy, and combination-regimen criteria for one of the listed oncology indications.Generally 6 months

    Continuation and Reauthorization

    Endometrial carcinoma maintenance — combination and maintenance therapy up to 20 total cycles

    Continuation is authorized for up to 20 total cycles when the requested medication is initially combined with carboplatin and paclitaxel and then continued as maintenance.

    Endometrial maintenance: Stage III-IV or recurrent endometrial carcinoma was treated with Keytruda Qlex, carboplatin, and paclitaxel, followed by Keytruda Qlex as single-agent maintenance.Up to 20 cycles total

    Continuation therapy — 6-month reauthorization subject to total or continuous-use limits

    Authorization of 6 months may be granted for continued treatment, subject to indication-specific total or continuous-use limits.

    Continuation therapy: The member is requesting reauthorization for a listed indication, remains on the indicated treatment, and has not experienced disease progression, disease recurrence where applicable, or unacceptable toxicity.Generally up to 24 months continuous use; specific adjuvant indications up to 12 months total; ASPS with axitinib up to 26 months total

    Prior Treatment Requirements

    StepCancer indicationRequired prior treatment or prerequisiteAdditional requirement
    1
    TMB-high solid tumor
    Disease must have progressed following prior treatment.
    No satisfactory alternative treatment options; tumor TMB must be ≥10 mutations/megabase.
    StepCancer indicationRequired prior treatment or prerequisiteAdditional requirement
    1
    Endometrial carcinoma
    For MSI-H or dMMR disease, progression following prior systemic therapy is required when the member is not a candidate for curative surgery or radiation.
    Treatment is as a single agent or in combination with lenvatinib, as applicable.
    1
    Epithelial ovarian, fallopian tube, or primary peritoneal carcinoma
    Platinum-resistant disease with one or two prior systemic treatment regimens.
    PD-L1 expression must be CPS ≥1; treatment is in combination with paclitaxel, with or without bevacizumab.
    StepCancer indicationRequired prior treatment or prerequisiteAdditional requirement
    1
    Adjuvant non-small cell lung cancer
    Prior adjuvant chemotherapy, or prior neoadjuvant therapy with the requested medication plus chemotherapy.
    Use as single-agent adjuvant therapy; required molecular testing must show no EGFR exon 19 deletion, EGFR exon 21 L858R mutation, or ALK, RET, or ROS1 fusion, unless testing is not feasible because of insufficient tissue.
    StepCancer indicationRequired prior treatment or prerequisiteAdditional requirement
    1
    Urothelial carcinoma
    Prior platinum or other chemotherapy is required for specified recurrent or metastatic settings; platinum ineligibility qualifies in other specified settings.
    Applicable settings include urethral, upper genitourinary tract, and prostatic urothelial carcinoma, as well as specified bladder cancer pathways; regimen may be single-agent therapy.
    StepCancer indicationRequired prior treatment or prerequisiteAdditional requirement
    1
    Follicular, oncocytic (Hürthle cell), or papillary thyroid carcinoma
    Disease progression on single-agent lenvatinib.
    Use the requested medication in combination with lenvatinib; disease must otherwise meet the specified disease extent and radioactive iodine criteria.
    StepCancer indicationRequired prior treatment or prerequisiteAdditional requirement
    1
    Gastric adenocarcinoma
    Subsequent-line treatment is required for applicable advanced, recurrent, or metastatic pathways.
    Regimen and biomarker requirements vary by surgical candidacy, HER2 status, MSI-H/dMMR or TMB-H status, and PD-L1 expression.
    1
    Esophageal or esophagogastric junction cancer
    Prior platinum-based chemotherapy or subsequent-line treatment is required for applicable advanced, recurrent, metastatic, or unresectable pathways.
    Subsequent single-agent therapy may require squamous histology with PD-L1 CPS ≥10; other pathways require the specified platinum/fluoropyrimidine regimen and biomarker status.
    StepCancer indicationRequired prior treatment or prerequisiteAdditional requirement
    1
    dMMR endometrial carcinoma
    Progression following prior platinum-based chemotherapy.
    Use in combination with lenvatinib for advanced, metastatic, or recurrent disease; the disease must be dMMR.

    Authorization, Documentation, and Denial Risks

    Prior Authorization

    Six-Month Authorization: Melanoma, NSCLC, and Head and Neck Cancer

    Six-month authorization may be granted for covered cutaneous melanoma, NSCLC, and head and neck cancer indications when the disease setting, biomarker findings, and requested regimen meet the applicable criteria.

    • Cutaneous melanoma: unresectable/metastatic single-agent therapy; subsequent or re-induction therapy with lenvatinib or with trametinib and dabrafenib for BRAF V600-mutated disease; neoadjuvant single-agent therapy; or adjuvant single-agent therapy after complete lymph-node resection or complete resection of stage IIB, IIC, or III disease in members age 12 or older.
    • NSCLC: recurrent, advanced, or metastatic disease; resectable neoadjuvant disease with platinum-containing chemotherapy for tumors ≥4 cm or node-positive disease; or adjuvant single-agent therapy after chemotherapy or neoadjuvant chemoimmunotherapy.
    • Head and neck cancer: resectable stage III-IVa non-nasopharyngeal HNSCC with PD-L1 ≥1, very advanced HNSCC or nasopharyngeal cancer meeting the listed biomarker or treatment criteria, or recurrent salivary gland tumors that are MSI-H, dMMR, TMB-H, or PD-L1 positive.
    Documentation Required

    Clinical Thresholds and Supporting Parameters

    Adjuvant melanoma age threshold
    Minimum age12 years and older
    DiseaseCutaneous melanoma
    Treatment settingAdjuvant treatment after complete resection of stage IIB, IIC, or III disease
    NSCLC PD-L1 TPS threshold
    BiomarkerPD-L1 expression
    MeasurementTumor Proportion Score (TPS)
    ThresholdTPS ≥1%

    Authorization Duration, Cycles, and Dosing

    Requested medication — standard six-month authorization
    MedicationRequested medication
    Authorization6 months
    BasisApplicable disease-specific criteria must be met
    Requested medication — up to 20 total cycles
    MedicationRequested medication
    MaximumUp to 20 total cycles
    IndicationStage III-IV or recurrent endometrial carcinoma maintenance

    Administration Setting

    Billing Rule

    Use the specified subcutaneous administration route

    The quantity-limit section specifies subcutaneous administration for Keytruda Qlex. Use the listed subcutaneous dosing schedule: 395/4,800 mg-units every 3 weeks or 790/9,600 mg-units every 6 weeks.

    Clinical Terms and Biomarkers

    TPS definition
    TermTumor Proportion Score (TPS)
    What it measuresPD-L1 expression
    Primary useCertain non-small cell lung cancer indications
    CPS definition
    TermCombined Positive Score (CPS)
    What it measuresPD-L1 expression
    UsesHead and neck, gastric, esophageal, GEJ, and cervical cancer indications

    Policy Background

    Keytruda Qlex is used across a broad range of solid and hematologic malignancy settings, including melanoma, non-small cell lung cancer, urothelial, gastrointestinal, gynecologic, renal cell, and Merkel cell cancers. Covered uses include single-agent and combination regimens, as well as neoadjuvant and adjuvant treatment, with eligibility sometimes determined by biomarkers such as PD-L1 expression, MSI-H, dMMR, or TMB-H.

    Policy Summary
    PayerBlue Cross Blue Shield - Tennessee
    PolicyPembrolizumab and Berahyaluronidase alfa-pmph (Keytruda Qlex)
    Policy CodePolicy ID_CHS_71972026b_1126
    Change TypeNo material change
    Effective DateJan 30, 2027
    Next Review DateN/A
    Key ActionSubmit applicable tumor biomarker, molecular, receptor, and laboratory documentation with the prior authorization request.
    SourceLink
    On This Page
    Covered Indications and EligibilityInitial Authorization PathwaysContinuation and ReauthorizationPrior Treatment RequirementsAuthorization, Documentation, and Denial RisksClinical Thresholds and Supporting ParametersAuthorization Duration, Cycles, and DosingAdministration SettingClinical Terms and BiomarkersPolicy Background
    Combination with carboplatin and paclitaxel or albumin-bound paclitaxel for squamous histology.

    Additional covered NSCLC settings

    • Neoadjuvant treatment with platinum-containing chemotherapy for resectable tumors ≥4 cm or node-positive disease, with the molecular criteria above.
    • Adjuvant single-agent therapy after adjuvant chemotherapy or after neoadjuvant therapy with the requested medication plus chemotherapy, with the molecular criteria above.
    Stage II, recurrent, locally advanced, or metastatic urothelial carcinoma treated in combination with enfortumab vedotin-ejfv.
    Unresectable, locally advanced, or metastatic neuroendocrine or adrenal tumors.
    No response to preoperative systemic therapy or recurrent unresectable/metastatic disease with MSI-H, dMMR, or TMB-H ≥10 mut/Mb.
  1. ANY of the following

    • HR-positive/HER2-negative disease treated subsequently after visceral crisis or endocrine-therapy refractoriness, when the member is not a candidate for fam-trastuzumab deruxtecan-nxki.
    • HER2-positive disease treated fourth line or beyond.
  2. Initial therapy — listed malignancies and disease-specific criteria

    Authorization of 6 months may be granted for the listed malignancies when the disease-specific criteria are met.

    Qualifying initial indication: The member has one of the listed malignancies and the requested medication meets the applicable treatment-line, biomarker, combination-regimen, or single-agent requirement.Disease-specific thresholds include PD-L1 CPS ≥1 and TMB-H ≥10 mut/Mb where stated

    Submit Required Laboratory Documentation

    Submit the supporting laboratory and pathology documentation needed to establish the requested indication and biomarker eligibility before prior authorization review.

    • PD-L1 expression, including CPS when applicable.
    • MSI-H, MMR, POLE/POLD1 status, and TMB results; document TMB-H as ≥10 mut/Mb and ultra-hypermutated colorectal or small-bowel tumors as TMB >50 mut/Mb when applicable.
    • HER2, estrogen, progesterone, and hormone-receptor status.
    • NSCLC driver testing documenting absence of EGFR exon 19 deletion, EGFR exon 21 L858R mutation, and ALK, RET, or ROS1 fusions, unless testing is infeasible because of insufficient tissue.
    Prior Authorization

    Six-Month Oncology Authorization

    Request six-month oncology authorization only when the disease-specific diagnosis, stage or treatment setting, biomarker status, prior therapy, and requested regimen satisfy the applicable coverage pathway.

    • Covered pathways include urothelial, solid-tumor, thyroid, colorectal, small-bowel, Merkel cell, gastric, esophageal/EGJ, cervical, ovarian/fallopian tube/primary peritoneal, uveal melanoma, endometrial, anal, and CNS brain-metastasis indications.
    • Requirements may include single-agent treatment, specified combination therapy, first-line or subsequent treatment, resectability or surgical candidacy, and required biomarker results.
    • Document platinum eligibility or prior therapy, prior progression, disease recurrence, and treatment setting whenever required by the indication.
    Prior Authorization

    Six-Month Authorization: Additional Indications

    Six-month authorization is available for the listed cancer indications only when the requested use matches the policy’s disease-specific setting and regimen requirements.

    • Covered additional indications include breast, prostate, pediatric diffuse high-grade glioma, ampullary, vaginal, pleural or peritoneal mesothelioma, penile, chordoma, and malignant histiocytic neoplasms.
    • Uveal melanoma is covered as single-agent treatment for unresectable or metastatic disease.
    • Anal carcinoma is covered with paclitaxel/carboplatin for recurrent or metastatic disease or as single-agent subsequent therapy; CNS brain metastases are covered as single-agent treatment for BRAF-nonspecific melanoma or PD-L1-positive NSCLC.
    Prior Authorization

    Breast Cancer Authorization Requirements

    For breast cancer, document receptor status, PD-L1 or other qualifying biomarkers, disease setting, and the required prior treatment or treatment sequence before requesting authorization.

    • Locally recurrent unresectable or metastatic TNBC requires HER2-, estrogen-, and progesterone-negative disease, PD-L1 CPS ≥10, and combination with sacituzumab govitecan-hziy or chemotherapy.
    • High-risk early-stage TNBC requires confirmed triple-negative status and neoadjuvant chemoimmunotherapy or continued single-agent adjuvant treatment after surgery.
    • Recurrent unresectable/metastatic or nonresponsive preoperative disease requires MSI-H, dMMR, or TMB-H ≥10 mut/Mb and the applicable HR-positive/HER2-negative or HER2-positive treatment line.
    • HR-positive/HER2-negative disease requires visceral crisis or endocrine-therapy refractory disease and inability to use fam-trastuzumab deruxtecan-nxki; HER2-positive disease requires fourth-line or later treatment.
    Prior Authorization

    Initial Authorization: Listed Malignancies and Regimens

    Initial authorization requires a listed malignancy and a regimen that matches the policy’s qualifying disease setting, biomarker, and line-of-therapy criteria.

    • Prostate: castration-resistant distant metastatic disease with TMB ≥10 mut/Mb.
    • Pediatric diffuse high-grade glioma: adjuvant therapy for hypermutant tumor or treatment of recurrent/progressive disease.
    • Ampullary adenocarcinoma: MSI-H, dMMR, or TMB-H ≥10 mut/Mb.
    • Vaginal, mesothelioma, penile, chordoma, and malignant histiocytic neoplasm requests must use the specified combination, first-line, subsequent, maintenance, or single-agent regimen.
    Prior Authorization

    Continuation Authorization and Duration Limits

    Continuation requests require reauthorization at six-month intervals and documentation that the member remains eligible for treatment without disease recurrence, progression, or unacceptable toxicity.

    • Adjuvant melanoma, HNSCC, TNBC, RCC, or NSCLC: up to 12 months total if no recurrence or unacceptable toxicity.
    • Most listed oncology indications: up to 24 months of continuous use if no progression or unacceptable toxicity.
    • Soft-tissue sarcoma: up to 26 months total with axitinib for ASPS, or up to 24 months as single-agent therapy.
    • Cutaneous melanoma and urothelial carcinoma have additional continuation rules, including adjuvant limits and specified combination-therapy pathways.
    Documentation Required

    Indication-Specific Prior Treatment Requirements

    Document the prior treatment sequence and response requirement specific to the requested indication; a qualifying diagnosis alone does not establish coverage.

    • Melanoma may require subsequent or re-induction therapy, prior complete resection for adjuvant treatment, or BRAF V600 mutation for trametinib/dabrafenib combination therapy.
    • NSCLC adjuvant requests require prior adjuvant chemotherapy or neoadjuvant therapy with the requested medication plus chemotherapy; thyroid combination therapy requires progression on single-agent lenvatinib.
    • Endometrial carcinoma with dMMR requires progression after prior platinum-based chemotherapy when treated with lenvatinib; other upper-GI and gynecologic indications require the specified first-line or subsequent setting and regimen.

    Unsupported block type: documentation

    Documentation Required

    MSI, MMR, POLE/POLD1, and TMB Results

    Submit laboratory reports establishing MSI-H, dMMR, POLE/POLD1 status, and TMB when those findings support eligibility.

    • TMB-H generally means ≥10 mutations/megabase; colorectal and small-bowel ultra-hypermutated criteria require TMB >50 mut/Mb.
    • Use the report to identify the tumor and the testing method or result supporting MSI-H, dMMR, POLE/POLD1, or TMB status.
    Documentation Required

    HER2 and Hormone-Receptor Testing

    Submit receptor testing reports when receptor status determines the covered indication or regimen.

    • Document HER2, estrogen, progesterone, and hormone-receptor results.
    • Breast TNBC requires negative HER2, estrogen, and progesterone results; gastric and esophageal regimens may require HER2 overexpression-positive or HER2-negative status.
    Documentation Required

    NSCLC Driver Testing

    For NSCLC requests, provide molecular testing documenting the relevant driver findings or explain why testing was not feasible because of insufficient tissue.

    • Document EGFR exon 19 deletion and exon 21 L858R mutation results.
    • Document ALK, RET, and ROS1 fusion results.
    • The policy requires absence of these findings for applicable NSCLC pathways unless testing is infeasible due to insufficient tissue.
    Documentation Required

    Clinical and Biomarker Documentation

    The clinical record must establish the diagnosis, stage, resectability, treatment setting, biomarker findings, and therapies used or planned.

    • For melanoma and NSCLC, document stage, resectability, recurrence or metastatic status, prior surgery or chemotherapy, and the requested neoadjuvant, adjuvant, maintenance, or subsequent regimen.
    • For head and neck cancer, document histology, stage, nasopharyngeal status, PD-L1 or other qualifying biomarker, and planned radiotherapy, cisplatin, cetuximab, or chemotherapy.
    • For thyroid, colorectal, and small-bowel cancers, document disease extent, RAI status when applicable, and qualifying MSI/MMR/POLE/POLD1/TMB results.
    Documentation Required

    Upper Gastrointestinal and Urothelial Documentation

    For urothelial, gastric, esophageal, and EGJ requests, document the disease subtype, stage, surgical candidacy, biomarker status, and exact regimen and line of therapy.

    • Urothelial documentation must identify bladder, urethral, upper-genitourinary-tract, or prostatic origin and the first-line, subsequent, adjuvant, BCG-unresponsive, or platinum-ineligible setting.
    • Gastric and esophageal/EGJ requests must document surgical candidacy or unresectability, HER2 status, PD-L1 CPS, MSI-H/dMMR or TMB-H status, and the specified chemotherapy or trastuzumab combination.
    • Document prior platinum or other chemotherapy where the policy requires subsequent treatment.
    Documentation Required

    Gynecologic Cancer Documentation

    For ovarian, fallopian-tube, primary-peritoneal, and endometrial cancer requests, document histology, recurrence or persistence, biomarker status, prior platinum therapy, and the requested combination or maintenance schedule.

    • Ovarian-family requests must identify the permitted histology and recurrent, persistent, platinum-resistant, or progressive setting, including PD-L1 CPS ≥1 when required.
    • Endometrial requests must document pMMR or dMMR status, prior platinum therapy and progression when required, or the stage III-IV/recurrent setting for carboplatin-paclitaxel followed by maintenance.

    Unsupported block type: documentation

    Denial Risk

    All Criteria and No Exclusions Required

    Coverage applies only when all applicable approval criteria are met and the member has no exclusion to the prescribed therapy.

    • Confirm the requested indication and regimen satisfy every applicable criterion.
    • Confirm that none of the policy exclusions apply before submitting the request.
    Denial Risk

    Unlisted Indications

    Uses outside the listed indications are considered experimental or investigational and are not medically necessary, except as potentially supported under the Tennessee off-label mandate.

    • Uveal melanoma is covered only under the specifically listed criteria for unresectable or metastatic disease.
    • Do not assume coverage for an unlisted indication based solely on clinical plausibility.
    Denial Risk

    Explicit Coverage Exclusions

    Coverage is excluded for pediatric members with TMB-H CNS cancer and for members whose disease progressed while receiving PD-1 or PD-L1 inhibitor therapy.

    • Review age, tumor site, TMB status, and treatment history before submission.
    • Document that progression did not occur during PD-1 or PD-L1 inhibitor therapy.
    Denial Risk

    Missing Required Testing

    Failure to submit required biomarker, receptor, or molecular documentation can result in denial or delay of prior authorization.

    • Missing PD-L1, MSI/MMR, POLE/POLD1, TMB, HER2, estrogen, progesterone, hormone-receptor, or NSCLC driver-test results may prevent approval.
    • If NSCLC molecular testing was not feasible because of insufficient tissue, document that reason explicitly.
    Denial Risk

    Disqualifying NSCLC Molecular Findings

    NSCLC requests may be denied when a disqualifying driver alteration is present or when the required molecular testing exception is not documented.

    • Disqualifying findings include EGFR exon 19 deletion, EGFR exon 21 L858R mutation, or ALK, RET, or ROS1 gene fusion.
    • For applicable pathways, approval requires absence of these alterations unless testing is infeasible because of insufficient tissue.
    Denial Risk

    Solid-Tumor Eligibility

    Solid-tumor authorization requires unresectable or metastatic disease that progressed after prior treatment, no satisfactory alternative treatment option, and either MSI-H/dMMR or TMB-H status.

    • The requested medication must be used as a single agent.
    • TMB-H means ≥10 mutations/megabase (mut/Mb).
    Denial Risk

    Thyroid Carcinoma Prerequisites

    For follicular, oncocytic (Hürthle cell), or papillary thyroid carcinoma, document locoregional unresectable, progressive or symptomatic, or metastatic disease; RAI status; and the qualifying biomarker or prior lenvatinib progression.

    • RAI must be not indicated, contraindicated, or unsuccessful.
    • The tumor must be MSI-H, dMMR, or TMB-H ≥10 mut/Mb, or the member must have progressed on single-agent lenvatinib when combination therapy is requested.
    Denial Risk

    Upper Gastrointestinal Cancer Requirements

    Upper-GI requests must satisfy the applicable surgical-candidacy, unresectability, biomarker, line-of-therapy, and regimen requirements.

    • Gastric cancer requires documentation of surgical candidacy or inoperability/unresectability and the applicable HER2, PD-L1, MSI-H, dMMR, or TMB-H status.
    • Esophageal/EGJ cancer requires surgical candidacy or unresectable/advanced disease, with the applicable PD-L1 CPS, HER2, MSI-H, dMMR, TMB-H, and first-line or subsequent regimen.
    Denial Risk

    Endometrial Carcinoma Requirements

    Endometrial carcinoma requests must document the applicable pMMR or dMMR status, prior platinum treatment and progression when required, and the approved treatment sequence.

    • Lenvatinib combination therapy is covered for pMMR disease or dMMR disease that progressed after prior platinum-based chemotherapy.
    • Single-agent therapy requires recurrent unresectable or metastatic MSI-H, dMMR, or TMB-H ≥10 mut/Mb disease.
    • Carboplatin/paclitaxel followed by single-agent maintenance is limited to stage III-IV or recurrent disease and up to 20 total cycles.
    Denial Risk

    Continuation: Progression, Recurrence, and Toxicity

    Continuation authorization requires evidence that treatment remains clinically appropriate and that the member has not experienced progression, recurrence where applicable, or unacceptable toxicity.

    • Adjuvant melanoma, HNSCC, TNBC, RCC, NSCLC, and urothelial carcinoma generally have a 12-month total limit.
    • Most other listed indications have a 24-month continuous-use limit; ASPS with axitinib may continue up to 26 months total.
    • Cutaneous melanoma and urothelial carcinoma have specific limits and combination-treatment continuation rules.
    Denial Risk

    Initial Authorization Denial Risks

    An initial request may be denied when the malignancy, biomarker, disease setting, treatment line, or regimen does not match the listed criteria.

    • Verify that the requested use is one of the listed indications and that all required biomarker thresholds and receptor results are present.
    • Verify the required combination partners, chemotherapy backbone, prior treatment, surgical status, and maintenance sequence.
    Denial Risk

    Tennessee Off-Label Recognition Standard

    An off-label request must meet Tennessee’s recognition standard for coverage of an FDA-approved drug used outside its FDA-labeled indication.

    • Provide evidence from a statutorily recognized standard reference compendium or published peer-reviewed medical literature.
    • Absent that support, the off-label use may not qualify for coverage under the state mandate.
    PD-L1 CPS threshold
    BiomarkerPD-L1 expression
    MeasurementCombined Positive Score (CPS)
    ThresholdCPS ≥1%
    Previously treated squamous esophageal or GEJ carcinoma PD-L1 threshold
    DiseasePreviously treated squamous esophageal or GEJ carcinoma
    Treatment lineSingle-agent subsequent therapy after one or more prior systemic therapy lines
    PD-L1 thresholdCPS ≥10%
    Age threshold for MSI-H/dMMR solid tumors and Merkel cell carcinoma
    Minimum age12 years and older
    Qualifying biomarkerMSI-H or dMMR solid tumors
    Additional indicationRecurrent locally advanced or metastatic Merkel cell carcinoma
    Resectable NSCLC tumor size or nodal eligibility
    DiseaseResectable non-small cell lung cancer
    Tumor sizeTumors ≥4 cm
    Nodal statusNode positive disease also qualifies
    NSCLC biomarker status and genomic aberration exclusion
    EGFR statusNo EGFR genomic tumor aberrations
    ALK statusNo ALK genomic tumor aberrations
    Applicable settingSpecified recurrent, advanced, metastatic, resectable, or adjuvant NSCLC
    TMB-high threshold
    BiomarkerTumor mutational burden-high (TMB-H)
    Threshold≥10 mutations/megabase (mut/Mb)
    TestingDetermined by an applicable laboratory test
    PD-L1 thresholds across listed indications
    Locally recurrent unresectable or metastatic TNBCPD-L1 CPS ≥10
    Specified ovarian cancer usePD-L1 CPS ≥1
    Resectable stage III-IVa non-nasopharyngeal HNSCCPD-L1 ≥1
    Cutaneous melanoma adjuvant eligibility
    DiseaseCutaneous melanoma
    Resection requirementComplete lymph node resection or complete resection of stage IIB, IIC, or III disease
    TreatmentSingle-agent adjuvant treatment
    Resectable NSCLC neoadjuvant eligibility
    DiseaseResectable NSCLC
    Tumor eligibilityTumor ≥4 cm or node positive
    TreatmentNeoadjuvant therapy with platinum-containing chemotherapy
    NSCLC actionable-driver exclusion
    EGFR exclusionsEGFR exon 19 deletion or EGFR exon 21 L858R mutation
    Gene-fusion exclusionsALK, RET, or ROS1 gene fusion
    ExceptionTesting is not feasible because of insufficient tissue
    TMB-high threshold across listed indications
    BiomarkerTumor mutational burden-high (TMB-H)
    Threshold≥10 mutations/megabase (mut/Mb)
    Listed usesHead and neck, solid tumor, thyroid, small bowel, gastric, esophageal/GEJ, and endometrial cancers
    Ultra-hypermutated POLE/POLD1 phenotype
    Associated genesPOLE/POLD1 tumor
    PhenotypeUltra-hypermutated
    Threshold>50 mut/Mb
    PD-L1 expression thresholds across listed indications
    Common thresholdCPS ≥1
    Subsequent squamous esophageal therapyCPS ≥10
    MeasurementCombined Positive Score (CPS) for PD-L1 expression
    Resectable NSCLC tumor size
    DiseaseResectable NSCLC
    Tumor size≥4 cm
    Alternative eligibilityNode positive disease
    Tumor mutational burden threshold
    BiomarkerTumor mutational burden-high
    Threshold≥10 mutations/megabase (mut/Mb)
    Listed usesEndometrial, pancreatic, biliary, occult primary, breast, and prostate cancers
    PD-L1 CPS for locally recurrent unresectable or metastatic TNBC
    Disease settingLocally recurrent, unresectable, or metastatic TNBC
    BiomarkerPD-L1 expression measured by CPS
    ThresholdCPS ≥10
    Endometrial maintenance duration
    DiseaseStage III-IV or recurrent endometrial carcinoma
    RegimenCarboplatin and paclitaxel followed by single-agent maintenance
    Maximum durationUp to 20 cycles total
    Prostate cancer TMB threshold
    DiseaseCastration-resistant distant metastatic prostate cancer
    TreatmentSingle-agent therapy
    TMB thresholdTMB ≥10 mutations/megabase
    TMB-high thresholds for vaginal and penile cancer indications
    Vaginal cancer thresholdTMB-H ≥10 mut/Mb
    Penile cancer thresholdTMB-H ≥10 mut/Mb
    Equivalent expression≥10 mutations/megabase
    Vaginal cancer PD-L1 threshold
    DiseaseRecurrent or metastatic vaginal cancer
    BiomarkerPD-L1 positive
    ThresholdCPS ≥1
    Requested medication — six-month authorization
    MedicationRequested medication
    Authorization period6 months
    Applicable usesEndometrial carcinoma, anal carcinoma, and CNS brain metastases
    Requested medication — up to 20 cycles total
    MedicationRequested medication
    MaximumUp to 20 cycles total
    Treatment contextCombination treatment followed by single-agent maintenance for endometrial carcinoma
    Keytruda Qlex — dosing options every three or six weeks
    RouteSubcutaneous
    Three-week option395/4,800 mg-units every 3 weeks
    Six-week option790/9,600 mg-units every 6 weeks
    Keytruda Qlex — subcutaneous dosing schedule
    ProductKeytruda Qlex
    AdministrationSubcutaneous dosing
    SchedulesEvery 3 weeks or every 6 weeks
    Keytruda Qlex — six-week and three-week dose options
    Six-week dose790/9,600 mg-units every 6 weeks
    Three-week dose395/4,800 mg-units every 3 weeks
    RouteSubcutaneous
    Keytruda Qlex — six-week and three-week dose options
    Three-week regimen395/4,800 mg-units every 3 weeks
    Six-week regimen790/9,600 mg-units every 6 weeks
    DrugKeytruda Qlex
    Keytruda Qlex — six-week and three-week dose options
    Dose option 1790/9,600 mg-units every 6 weeks
    Dose option 2395/4,800 mg-units every 3 weeks
    Administration routeSubcutaneous
    Keytruda Qlex — dosing options every three or six weeks
    MedicationKeytruda Qlex
    Available frequencyEvery 3 or 6 weeks
    Dose amounts395/4,800 or 790/9,600 mg-units
    Keytruda Qlex — dosing options every three or six weeks
    RouteSubcutaneous
    Three-week dose395/4,800 mg-units every 3 weeks
    Six-week dose790/9,600 mg-units every 6 weeks
    Keytruda Qlex — dosing options every three or six weeks
    ProductKeytruda Qlex
    Schedule 1395/4,800 mg-units every 3 weeks
    Schedule 2790/9,600 mg-units every 6 weeks
    Keytruda Qlex — dosing options every three or six weeks
    AdministrationSubcutaneous
    Standard three-week dose395/4,800 mg-units
    Standard six-week dose790/9,600 mg-units
    Keytruda Qlex — dosing options every three or six weeks
    Frequency choicesEvery 3 weeks or every 6 weeks
    Three-week amount395/4,800 mg-units
    Six-week amount790/9,600 mg-units
    Keytruda Qlex — dosing options every three or six weeks
    MedicationKeytruda Qlex
    RouteSubcutaneous
    Maximum dosing options395/4,800 mg-units every 3 weeks or 790/9,600 mg-units every 6 weeks
    Keytruda Qlex — dosing options every three or six weeks
    Three-week option395/4,800 mg-units every 3 weeks
    Six-week option790/9,600 mg-units every 6 weeks
    RouteSubcutaneous
    Keytruda Qlex — dosing options every three or six weeks
    MedicationKeytruda Qlex
    Three-week dose395/4,800 mg-units every 3 weeks
    Six-week dose790/9,600 mg-units every 6 weeks
    MSI-H and dMMR definitions
    MSI-HMicrosatellite instability-high
    dMMRMismatch repair deficient
    UseQualifying tumor biomarkers for specified solid tumor indications
    TMB-H definition
    TermTumor mutational burden-high (TMB-H)
    ThresholdAt least 10 mutations per megabase
    Unitmut/Mb
    pMMR or not MSI-H definition
    pMMRMismatch repair proficient
    Not MSI-HTumor is not microsatellite instability-high
    TestingStatus determined by an FDA-approved test
    MSI-H or dMMR definition
    MSI-HMicrosatellite instability-high
    dMMRMismatch repair deficient
    TestingStatus determined by an FDA-approved test
    PD-L1 CPS definition
    TermPD-L1 Combined Positive Score (CPS)
    Reported thresholdsCPS ≥1 and CPS ≥10
    Related reportingSome indications specify PD-L1 ≥1
    MSI-H definition
    AbbreviationMSI-H
    MeaningMicrosatellite instability-high
    Policy roleTumor biomarker used as an eligibility criterion
    dMMR definition
    AbbreviationdMMR
    MeaningMismatch repair deficient
    Policy roleTumor biomarker used as an eligibility criterion
    TMB-H definition
    AbbreviationTMB-H
    MeaningTumor mutational burden high
    General thresholdAt least 10 mutations per megabase
    CPS definition
    AbbreviationCPS
    Full termCombined Positive Score
    PurposeQuantifies PD-L1 expression
    Ultra-hypermutated phenotype definition
    PhenotypeUltra-hypermutated tumor phenotype
    Associated tumorsPOLE/POLD1 tumors
    ThresholdTMB greater than 50 mutations per megabase
    MSI-H definition
    AbbreviationMSI-H
    MeaningMicrosatellite instability-high
    UseQualifying tumor status in listed cancer indications
    dMMR definition
    AbbreviationdMMR
    MeaningMismatch repair deficient
    UseQualifying tumor status in listed cancer indications
    TMB-H definition
    TermTumor mutational burden-high (TMB-H)
    DefinitionAt least 10 mutations per megabase
    Unitmut/Mb
    PD-L1 CPS definition for TNBC
    TermPD-L1 Combined Positive Score (CPS)
    TNBC thresholdCPS ≥10
    Applicable settingLocally recurrent unresectable or metastatic TNBC
    TNBC definition
    AbbreviationTNBC
    MeaningTriple-negative breast cancer
    Receptor statusHER-2, estrogen, and progesterone receptor negative
    RCC definition
    AbbreviationRCC
    Full termRenal cell carcinoma
    Policy useIncludes advanced, relapsed, stage IV, and specified adjuvant treatment
    ASPS definition
    AbbreviationASPS
    Full termAlveolar soft part sarcoma
    Treatment contextSingle-agent therapy or combination with axitinib
    UPS definition
    AbbreviationUPS
    Full termUndifferentiated pleomorphic sarcoma
    Treatment contextNeoadjuvant radiation followed by single-agent adjuvant therapy
    TMB-H definition for listed indications
    TermTumor mutational burden-high (TMB-H)
    ThresholdAt least 10 mutations per megabase (mut/Mb)
    Listed examplesProstate, ampullary, vaginal, and penile cancers
    MSI-H/dMMR definition
    BiomarkersMSI-H and dMMR
    MSI-H meaningMicrosatellite instability-high
    dMMR meaningMismatch repair deficient
    PD-L1 positive vaginal cancer definition
    DefinitionPD-L1 positive vaginal cancer
    MeasurementCombined Positive Score (CPS)
    ThresholdCPS ≥1